Andre Goy, MD, discusses the results from a small clinical trial, which was presented at the 2019 American Society of Hematology Annual Meeting that he found particularly significant for the treatment of patients with relapsed/refractory mantle cell lymphoma.
Andre Goy, MD, chief in the Division of Lymphoma, chairman and director at John Theurer (JT) Cancer Center, discusses the results from a small clinical trial, which was presented at the 2019 American Society of Hematology (ASH) Annual Meeting that he found particularly significant for the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL).
Although it was a small study, Goy says the results from the combination of venetoclax (Venclexta) plus ibrutinib (Imbruvica), a biological combination, demonstrated an impressive complete response rate, as well as impressive minimal residual disease-negativity, in patients with relapsed/refractory MCL. However, what was most impressive with this combination was that some patients had to stop treatment for different reasons, but that a number of these patients remained in remission 18 months after treatment discontinuation.
It is unheard of that patients could continue to receive benefit from a biological combination after discontinuing treatment, Goy says. This demonstrates the potential to stop therapy in patients with relapsed/refractory MCL. Goy concludes that these findings may be critical in the treatment landscape of MCL.
<< View more resources and information regarding mantle cell lymphoma
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma
March 26th 2024Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Read More